News

Bayer CropScience signs R&D pact
Enlarge image

ResearchGermany

Bayer CropScience signs R&D pact

06.09.2012 - Bayer CropScience and US firm Mendel Biotechnology will co-develop a herbicide resistance breaking technology.

The focus of the new multi-year collaboration with the US plant genomics specialist is to jointly identify herbicides with novel modes of action, because many weeds have developed resistance to multiple herbicide classes. Under the terms of the agreement, the global No. 2 in herbicides, will bring in its expertise in herbicide research and development. Mendel will contribute its knowledge of plant genetic regulatory networks (PGRNs) – especially its know-how on regulatory transcription factors that can contribute to herbicide resistance. 
  

“We believe that this collaboration will help us continue our significant contributions in agricultural chemistry“, quoted Dr. C. David Nicholson, Global Head of Research & Development at Bayer CropScience. He added he hoped the combined know-how would  help growers to tackle weed resistance issues and to protect their crops.”



Mendel has already partnered with the Germans in identifying chemicals that modulate the plant’s stress response signalling networks. The company has extensive knowledge on the set of transcription factors and regulatory networks in different plants identified by 1st PGRN platform and hold patents on cold and drought resistance

http://www.european-biotechnology-news.com/news/news/2012-03/bayer-cropscience-signs-rd-partnership.html

Industry reportGermany

27.04.2016 More revenue, more jobs, more financing, more R&D expenditure – all signs point towards sustainable growth in the German biotech sector. These are the results of the most recent company survey 2016, published by biotechnologie.de. The report was once again conducted alongside the biotech standards defined by the organisation for economic cooperation and development (OECD).

Clinical ResearchFrancePortugal

21.04.2016 An expert panel’s final report on the fatal drug trial earlier this year in France states that the death of one of the participants was most likely caused by the drug’s toxicity and not by any violation of the rules.

Immuno-oncologyNetherlandsBelgium

21.04.2016 For up to US$685m (€606m), Dutch ArgenX has outlicensed its human antibody programme ARGX-115 to AbbVie. The pre-clinical immuno-oncology candidate targets a protein believed to contribute to immunosuppressive effects of T-cells.

RegulatorySwitzerlandEU

20.04.2016 The US government is forking out up to US$100m to get Basilea Pharmaceutica’s broad-spectrum antibiotic ceftobiprole on the US market. In the EU, ceftobiprole is already available.

Immuno-oncologyUK

19.04.2016 British drug developer Heptares Therapeutics and mAb maker Kymab Ltd have partnered up in yet another immuno-oncology collaboration. The companies plan to discover antibody meds targeting a superfamily of receptors.

FinancingSwitzerlandFranceEUGermanyDenmark

15.04.2016 Not every company is put off by the current stock market climate. Swiss biopharma company GeNeuro has gone public at Euronext Paris, raising €33m in the process. Others, meanwhile, have to find different ways to raise money.

Event ReviewSwitzerlandBelgiumEU

13.04.2016 Despite political disturbances, 2015 was a good year for the biotech scene in Switzerland. Net sales increased by 5.1% to CHF5,133m and 400 additional people found jobs in the sector. As usual, the new numbers were presented at the annual Swiss Biotech Day – which set new records as well.

FinancingGermanyNetherlandsEU

12.04.2016 German-Dutch life science investment specialist Forbion Capital Partners has raised more than €180m for its venture capital fund Forbion Capital Fund III. Once more the money will primarily go to European start-ups.

Event ReviewGermanyEU

08.04.2016 Do you win by being innovative?, was the question asked at this year’s DIA Euromeeting in Hamburg. In a relaxed and cooperative atmosphere, regulators, physicians and patients had ample opportunity to interact with the healthcare industry.

M&AIrelandEU

07.04.2016 Pfizer and Allergan have called off their merger, cancelling plans to relocate the US pharma giant to Ireland to avoid US taxation. The US government has put a spoke in Pfizer’s wheels - an unfair move, Allergan says.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

München

BioVaria 2016

Berlin (GER)

XIV. BIONNALE 2016

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • BIOTIE THERAPEUTICS (FI)0.27 EUR92.86%
  • PLETHORA (UK)3.38 GBP12.67%
  • FORMYCON (D)24.56 EUR5.59%

FLOP

  • SERODUS (N)1.46 NOK-14.12%
  • PHOTOCURE (N)39.50 NOK-7.49%
  • BIONOR PHARMA (N)0.79 NOK-7.06%

TOP

  • AB SCIENCE (F)18.84 EUR71.3%
  • SYNAIRGEN (UK)35.75 GBP45.9%
  • BIOFRONTERA (D)3.17 EUR36.1%

FLOP

  • SERODUS (N)1.46 NOK-28.8%
  • THERAMETRICS (CH)0.03 CHF-25.0%
  • OREXO (S)50.00 SEK-19.4%

TOP

  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • KARO BIO (S)31.20 SEK2022.4%
  • NICOX (F)8.55 EUR352.4%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)6.10 SEK-88.0%
  • BB BIOTECH (D)46.44 EUR-82.3%
  • BIOTEST (D)16.69 EUR-76.5%

No liability assumed, Date: 01.05.2016